The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Education
  • Non-profit
  • Books
  • Technology

U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
The PennZone/10307371

Trending...
  • DivX Unveils Revamped Resource Guide to Help Users Easily Convert MKV to MP4
  • $10 Million Controlling Interest Acquisition Completed for Concerts.com & TicketStub.com by Emerging Sports, Entertainment & Gaming AI Powered Company
  • AI Transforming the POD Industry: Innovations and Opportunities
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T) therapy for the treatment of neuroblastoma. Under the leadership of Prof. John Maris, a functionally relevant and highly specific protein, called PHOX2B, was identified in neuroblastoma cells and the team elucidated that a peptide from PHOX2B could serve as an excellent target for an immunotherapy to treat this devastating disease.

Myrio developed a highly specific binder to the PHOX2B peptide-major histocompatibility complex (p-HLA) target using its unique ReDTM technology. In collaboration with the hospital, the Myrio binder has been engineered into a CAR-T product. Importantly, unlike other binders which target a single HLA-allotype, Myrio's binder is capable of recognizing the peptide in multiple HLA-allotypes, a phenomenon referred to as breaking HLA restriction, which offers the opportunity to treat a broader population of patients using the same immunotherapy.

This groundbreaking approach was detailed in a publication by Myrio, in the journal Nature titled "Targeting of intracellular oncoproteins with peptide-centric CARs."[1] in November 2023.

This is the first time a binder developed by Myrio will enter a human trial and is a major validation of the company's technology, building on the significant insights shared in their joint research.

"Neuroblastoma is the most common tumor of the sympathetic nervous system, the most common malignancy of infancy and accounts for 15% of pediatric cancer-related deaths", said Prof. Maris. The current treatment options for patients with high-risk neuroblastoma are associated with low response rates and significant toxicities and the development of new treatment options is desperately needed. This investigational immunotherapy has the potential to be a major advance for patients suffering from this devastating disease".

More on The PennZone
  • Leading Retirement Expert Michael Seibert Featured on CNBC
  • Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
  • RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline
  • Exeter Smiles in Allentown Enhances Orthodontic Precision with DIBS AI Technology
  • Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity

The Phase 1 clinical trial entitled "PHOX2B Peptide-Centric Chimeric Antigen Receptor Autologous T cells (PHOX2B PC-CAR T) for Relapsed Neuroblastoma will be conducted under the leadership of Prof. Maris and it is anticipated that the first patient will be enrolled mid-year 2025.

Dr Graeme Wald, CEO of Myrio Therapeutics commented "that this is a major step forward for Myrio. It is the culmination of many years of work at Myrio in developing bispecific binders to Human Leukocyte Antigens for the treatment of solid tumours."

About Neuroblastoma

Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months.[2] The annual incidence of neuroblastoma in the United States is approximately 800 cases, and it accounts for 15% of pediatric cancer-related deaths.3 Due to the high variability in its presentation, clinical signs and symptoms at presentation can range from a benign palpable mass with distension to major illness from substantial tumor spread. Although overall increases in five-year event-free survival have been reported, this has come at the cost of significant life threating treatment-related side effects, and subgroup-specific analysis of mortality has revealed discordance between the high cure rates for the more benign low-risk forms and little improvement in the high-risk groups.[3],[4],[5]

About Myrio

Myrio is a privately held company based in Melbourne Australia. It has developed an entirely novel discovery platform, Retained Display (ReDTM), which is geared towards the discovery of highly stable, full human, scFv binders against peptides presented on the surface of solid cancer cells as presented by the HLA complex. These binders have repeatedly shown their utility in bispecific T-Cell Engager or CAR-T formats to direct cytotoxicity against pHLA specific target tumour cells. In the case of a bispecific T-Cell Engager the molecule binds to both the pHLA and a T-cell – the T-cell then kills the tumour cell. In the case of a CAR-T therapy, the antibody is expressed on the surface of a CAR-T cell targeting it against the pMHC, directing the killing of the tumour cell.

More on The PennZone
  • Chasing Creative Plants Roots in Palm Coast, Builds Marketing Systems for Modern B2B Brands
  • Shane Victorino & Together We Dance Foundation Host Special Needs Families at Phillies Game
  • David M. White, DDS Celebrates 500 Five-Star Reviews in Reno
  • Medical Guardian Offers Mom's Meals® Benefit to Help Members Recover at Home and Prevent Hospital Readmission
  • BJ Simmons Releases Trapped In



[1] Mark Yarmarkovich, Quinlen F. Marshall, John M. Warrington, Rasika Premaratne, Alvin Farrel et al. Targeting of intracellular oncoprotiens with peptide-centric CARs. Nature. 2023 Nov 623 (7988): 1-8.



[2] London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20;23(27):6459-65.



[3] Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010 Jun 10;362(23):2202-11.



[4] Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007 Jun 23;369(9579):2106-20.



[5] Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008 Nov 01;113(9):2575-96.


SOURCE Myrio Therapeutics
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Exposing Psychiatric Abuse, CCHR Has Pushed for Global Human Rights Protections
  • Doosan Robotics Accelerates Push to Become an AI Robot Solutions Leader
  • RDG Mining launches 1-day XRP、BTC mining contract, XRP short-term investment users surge 500%
  • Donna Cardellino and Paul Lafrance Sign Exclusive Deal for Worldwide Expansion into Commercial and Luxury Real Estate Design Projects
  • New Book "Three Permissions" Redefines Self-Leadership for a Burnout-Weary Culture
  • Opening a new era of USDC smart cloud mining: CJB Crypto makes digital dollar earnings within reach
  • Revolutionizing Floor Care in the Lehigh Valley: Share Advanced Offers 5-Step Deep Cleaning Process
  • The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
  • Philadelphia HVAC Company Bypasses Paid Search Ads, Citing Cost Savings for Customers
  • Block AI Labs Empowers Startups with Affordable, AI-Driven Software Development from U.S. and Colombia Ask ChatGPT
  • DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of The McKenzie Memorial Hospital Customers Whose Data May Have Been Compromised
  • Peer Support Alliance to Launch First-Ever 24/7 Peer Support App for Adults with Mental Illness
  • Berger Montague PC Investigates Securities Claims Against RxSight, Inc. (NASDAQ: RXST)
  • "The U.S. is Running Out of Workers" – New Book Offers Urgent, Research-Backed Solution to the Workforce Crisis
  • LandGate® Releases Q2 2025 U.S. Data Center Development Summary
  • Inspiring Speakers & the World Championship of Public Speaking® Coming to Toastmasters International Convention
  • 123Invent Inventor Develops Device to Protect Against Gunfire (CTK-1678)
  • Macon's Historic Douglass Theatre Names Toni Simmons Henson as Artistic Director for Inaugural Series Celebrating the Spirit of American Theatre
  • The New Evangelicals Announces New Executive Director and Expanded Leadership Team
  • Bringing AI Innovations to the Job Site, Shly and LATO AI Boost Client Satisfaction

Popular on PennZone

  • DimHum Launches Revolutionary CrowdShipping Service - 118
  • VIP Vacations Recognized as a 2024 Top Selling Travel Agency by the Jamaica Tourism Board - 109
  • Digital Watchdog Launches New myDW Cloud Services
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Be Part of the World's Largest Art Biennale | Moons, Castles, Trees | Copenhagen Chronotopes
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • #ChipInChipAway at Hunger Taking Place on July 10th, 2025
  • Exelon Leader Tamla Olivier Named 2025 Technologist of the Year by Waves of Change STEM Conference
  • Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment

Similar on PennZone

  • Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
  • YPTC Wins #1 Best Place to Work in Philadelphia
  • RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline
  • Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity
  • Chasing Creative Plants Roots in Palm Coast, Builds Marketing Systems for Modern B2B Brands
  • Medical Guardian Offers Mom's Meals® Benefit to Help Members Recover at Home and Prevent Hospital Readmission
  • TNT Removal & Disposal Celebrates Record Year Helping Pennsylvania Property Owners Reclaim Space
  • Postmortem Pathology Offers Expert Autopsy Services with Dignity and Accuracy
  • Private Autopsies Provide Families in Colorado with Answers and Closure
  • Vijay Tirathrai named Managing Director in Dubai, UAE
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us